Senhwa Biosciences, Inc. (TPEX:6492)
Taiwan
· Delayed Price · Currency is TWD 33.35
+0.25 (0.76%)
May 14, 2025, 11:45 AM CST
Senhwa Biosciences Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 1 | 1 | 1 | 1 | 0.55 | 0.62 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | 81.82% | -10.86% | 105.67% | Upgrade
|
| Cost of Revenue | 0.53 | 0.52 | 0.45 | 0.5 | 0.23 | 0.27 | Upgrade
|
| Gross Profit | 0.47 | 0.48 | 0.55 | 0.51 | 0.32 | 0.35 | Upgrade
|
| Selling, General & Admin | 63.11 | 62.93 | 54.79 | 43.77 | 71.17 | 83.24 | Upgrade
|
| Research & Development | 241.75 | 243.74 | 256.87 | 312.85 | 275.47 | 276.37 | Upgrade
|
| Operating Expenses | 304.86 | 306.67 | 311.66 | 356.62 | 346.64 | 359.61 | Upgrade
|
| Operating Income | -304.39 | -306.19 | -311.11 | -356.12 | -346.32 | -359.26 | Upgrade
|
| Interest Expense | -0.63 | -0.66 | -0.54 | -0.54 | -0.53 | -0.26 | Upgrade
|
| Interest & Investment Income | 6.7 | 6.11 | 7.64 | 7.32 | 4.61 | 4.02 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.19 | -1.19 | 0.49 | -1 | 1.24 | 0.43 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.15 | 0.8 | - | 0.01 | 0.92 | 0.2 | Upgrade
|
| EBT Excluding Unusual Items | -299.36 | -301.14 | -303.52 | -350.34 | -340.06 | -354.87 | Upgrade
|
| Gain (Loss) on Sale of Investments | 8.68 | 8.68 | 8.04 | 2.08 | 1.52 | 0.49 | Upgrade
|
| Other Unusual Items | - | - | 0.43 | - | 10.2 | - | Upgrade
|
| Pretax Income | -290.69 | -292.46 | -295.05 | -348.26 | -328.35 | -354.38 | Upgrade
|
| Income Tax Expense | 1.28 | 1.28 | 1.26 | 1.37 | 0.91 | 0.5 | Upgrade
|
| Net Income | -291.97 | -293.75 | -296.31 | -349.63 | -329.26 | -354.88 | Upgrade
|
| Net Income to Common | -291.97 | -293.75 | -296.31 | -349.63 | -329.26 | -354.88 | Upgrade
|
| Shares Outstanding (Basic) | 89 | 89 | 89 | 89 | 90 | 79 | Upgrade
|
| Shares Outstanding (Diluted) | 89 | 89 | 89 | 89 | 90 | 79 | Upgrade
|
| Shares Change (YoY) | - | - | -0.00% | -0.50% | 13.49% | 6.06% | Upgrade
|
| EPS (Basic) | -3.27 | -3.29 | -3.32 | -3.92 | -3.67 | -4.49 | Upgrade
|
| EPS (Diluted) | -3.27 | -3.29 | -3.32 | -3.92 | -3.67 | -4.49 | Upgrade
|
| Free Cash Flow | -279.82 | -296.17 | -299 | -400.34 | -300.29 | -273.07 | Upgrade
|
| Free Cash Flow Per Share | -3.14 | -3.32 | -3.35 | -4.49 | -3.35 | -3.46 | Upgrade
|
| Gross Margin | 47.00% | 47.70% | 55.20% | 50.50% | 58.73% | 56.89% | Upgrade
|
| Operating Margin | -30439.40% | -30619.10% | -31111.10% | -35611.50% | -62966.54% | -58226.74% | Upgrade
|
| Profit Margin | -29196.50% | -29374.50% | -29630.60% | -34963.20% | -59864.91% | -57516.69% | Upgrade
|
| Free Cash Flow Margin | -27982.40% | -29617.30% | -29900.10% | -40034.00% | -54597.64% | -44257.86% | Upgrade
|
| EBITDA | -302.09 | -303.94 | -309.53 | -355.81 | -345.86 | -357.94 | Upgrade
|
| D&A For EBITDA | 2.31 | 2.25 | 1.58 | 0.31 | 0.46 | 1.32 | Upgrade
|
| EBIT | -304.39 | -306.19 | -311.11 | -356.12 | -346.32 | -359.26 | Upgrade
|
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.